AZGP1 and prostate carcinoma: A multicenter study focusing on the association between the expression level of AZGP1 and the prognosis of patients with prostate cancer showed that decreased expression of AZGP1 was related to poor prognosis and recurrence of prostate cancer (Brooks et al., 2016).